PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Pacific Biosciences of California, Inc.

Annual Report on Form 10-K

For the Fiscal Year Ended December 31, 2025

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K, including the sections titled “Business,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contain or may contain forward-looking statements that are based on the beliefs and assumptions of the management of Pacific Biosciences of California, Inc. (the “Company,” “we,” “us,” or “our”) and on information currently available to our management. The statements contained in this Annual Report on Form 10-K that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and include, but are not limited to:

•the availability, uses, accuracy, sensitivity, advantages, compatibility, pricing, specifications, quality, or performance of, or benefits or expected benefits of using, our products or technologies, including the Revio® and Vega TM systems, and our expectations regarding HiFi sequencing;

•our expectations, estimates and assumptions about the Asset Sale (as defined below), including our expectations with respect to timing and payment to the former equity holders of Apton (as defined below) and the satisfaction of the related milestone obligations related to our acquisition of Apton;

•our expectations regarding commercial availability and lowering the cost of long-read sequencing through SPRQ-Nx chemistry;

•our expectations regarding the development of kitted-solutions, like our Kinnex Full-length RNA kits and PureTarget;

•our current and future products;

•improvements to our existing products;

•our strategic and commercial plans, including our expectations regarding our clinical strategy and Revio and Vega systems;

•our market opportunity, including market size and expected market growth;

•our expectations regarding the timing and conversion of backlog to revenue and the pricing and gross margin for products;

•our manufacturing plans including developing and scaling of manufacturing and delivery of our products;

•any reductions or potential reductions in academic or government funding, including for the National Institutes of Health (“NIH"), or targeted cancellations by the U.S. federal government of certain grants or contracts, could negatively impact our customers and reduce demand for our products and services;

•our research and development plans;

•expected timing of payment of certain intangible assets;

•the anticipated impact of catastrophic events, including health epidemics or pandemics and military or other armed conflicts, on our business, business plans and results of operations;

•uncertainty regarding or potential changes in diplomatic and trade relationships as a result of the recent change in the U.S. government administration;

•the impact of tariffs recently imposed by the U.S. government and its trading partners in response, other possible tariffs or trade protection measures, import or export licensing requirements, new or different customs duties, trade embargoes and sanctions and other trade barriers;

•our product development plans, roadmaps, and objectives, including, among other things, statements relating to future uses, quality, or performance of, or benefits of using, products or technologies, updates, or improvements of our products;

•our intentions regarding seeking regulatory approval for our products;

•our competitive landscape, including competition in the long-read sequencing technologies market;

•our expectations regarding collaborations and partnerships;

•our expectations regarding unrecognized income tax benefits;

•our expectations regarding market risk, including interest rate changes and general macroeconomic conditions;

•the sufficiency of cash, cash equivalents, and investments to fund projected operating requirements;

•the effects of recent accounting pronouncements on our financial statements; and

•other future events.

Forward-looking statements can be identified by words such as: “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “should,” “target,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading “Risk Factors” in this report and in other documents we file with the Securities and Exchange Commission ("SEC"). Given these risks and uncertainties, you should not place undue reliance on forward-looking statements. Also, forward-looking statements represent management’s beliefs and assumptions as of the date of this report. Except as required by law, we assume no obligation to update forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

This Annual Report on Form 10-K also contains estimates, projections, and other information concerning our industry, our business, and the markets for our products, including data regarding the estimated size and estimated growth for those markets. Information that is based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources.